No Data
No Data
"Do not sell if prices do not drop"! Trump enforces a cap on the minimum drug prices for developed countries, but a litigation battle may 'replay'.
① An executive order signed on the 12th of October, USA time, requires that the payment price of pharmaceuticals in the USA be forcibly anchored to the lowest level of other developed countries within 30 days; ② There is strong opposition within the USA, and industry experts estimate that a legal battle is about to "replay"; ③ As the market-oriented USA begins to wield the big stick of administrative pricing, the underlying rules of the game for Innovative Drugs have quietly been rewritten.
Zhejiang Huahai Pharmaceutical (600521): Active Pharmaceutical Ingredient demonstrates resilience, Innovative Drugs value becomes evident.
The performance for 2024 and Q1 2025 meets market expectations. For 2024: revenue is 9.547 billion yuan, +14.91% year-on-year, Net income attributable to the parent company is 1.119 billion yuan, +34.74% year-on-year, and the net income attributable to the parent after deducting non-recurring items is 1.
Huahai Pharmaceutical: Zhejiang Huahai Pharmaceutical Co., Ltd. 2024 Annual Report Summary
Huahai Pharmaceutical: Zhejiang Huahai Pharmaceutical Co., Ltd. 2024 Annual Report
Huahai Pharmaceutical: Zhejiang Huahai Pharmaceutical Co., Ltd. Report for the first quarter of 2025
Zhejiang Huahai Pharmaceutical Co., Ltd. 2024 Annual Report